Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell even higher, with the expectation that established trends will continue [1] Company Overview: Mineralys Therapeutics, Inc. (MLYS) - MLYS currently holds a Momentum Style Score of A, indicating strong momentum characteristics [3] - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook compared to the market [4] Performance Metrics - Over the past week, MLYS shares increased by 4.78%, outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 0.92% [6] - In a longer timeframe, MLYS shares have shown a monthly price change of 14.98%, significantly higher than the industry's 3.03% [6] - Over the last quarter, MLYS shares surged by 60.56%, while the S&P 500 index declined by 2.26% during the same period [7] - Year-to-date, MLYS shares are up 18.08%, compared to the S&P 500's increase of 13.85% [7] Trading Volume - MLYS has an average 20-day trading volume of 794,549 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the past two months, two earnings estimates for MLYS have been revised upwards, while none have been lowered, leading to an increase in the consensus estimate from -$4.36 to -$3.77 [10] - For the next fiscal year, two estimates have also moved upwards with no downward revisions [10] Conclusion - Given the strong performance metrics and positive earnings outlook, MLYS is positioned as a promising investment opportunity with a Momentum Score of A and a Zacks Rank of 2 (Buy) [12]

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Benitec Biopharma Limited (BNTC) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Benitec Biopharma Limited is a member of our Medical group, which inclu ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post a loss of $0.13 per share when it actually produced a loss of $0.12, delivering a surprise of 7.69%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.RenovoRx, which belongs to the Zacks Medical ...

Alpha Cognition Inc. (ACOG) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.75 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 65.52%. A quarter ago, it was expected that this company would post a loss of $0.48 per share when it actually produced a loss of $0.51, delivering a surprise of -6.25%.Over the last four quarters, the company has sur ...

Group 1 - Gossamer Bio reported a quarterly loss of $0.16 per share, better than the Zacks Consensus Estimate of a loss of $0.18, and an improvement from a loss of $0.19 per share a year ago, resulting in an earnings surprise of 11.11% [1] - The company achieved revenues of $9.89 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 167.27%, compared to zero revenues a year ago [2] - Gossamer Bio shares have increased approximately 11.7% since the beginning of the year, outperforming the S&P 500's gain of 0.2% [3] Group 2 - The earnings outlook for Gossamer Bio is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.18 on revenues of $4.13 million, and -$0.66 on revenues of $26.3 million for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which Gossamer Bio belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] Group 3 - Gossamer Bio has surpassed consensus EPS estimates three times over the last four quarters, indicating a positive trend in earnings performance [2] - The estimate revisions trend for Gossamer Bio is currently mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6]

Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 5.88%. A quarter ago, it was expected that this company would post a loss of $0.34 per share when it actually produced a loss of $1.27, delivering a surprise of -273.53%.Over the last four quarters, the company has surp ...

Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -250%. A quarter ago, it was expected that this company would post a loss of $0.25 per share when it actually produced a loss of $0.15, delivering a surprise of 40%.Over the last four quarters, the company has surpassed cons ...

Precision BioSciences (DTIL) came out with a quarterly loss of $2.21 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.35 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -413.95%. A quarter ago, it was expected that this genome editing company would post a loss of $0.42 per share when it actually produced a loss of $3.20, delivering a surprise of -661.90%.Over the last four quarters, ...